top of page
Nonacus Website Materials_Hero Banner.png

Taking the next step
in comprehensive genomic profiling 

NEWS

About Us

Advanced Genomics APAC is a subsidiary of the UK-based group company Advanced Genomics Limited. It primarily operates the Nonacus product, with Taiwan as its base, to expand into markets such as Japan, Korea, Australia, New Zealand, Mainland China, and Southeast Asia. Our core value lies in providing cutting-edge testing technology from top research institutions to hospitals, clinics, laboratories, enterprises, and patients, along with excellent testing equipment and technical support.

Nonacos Website Materials_Section Banner.jpg
Lab-hood-1102x896-1.jpeg

About Nonacus

In 2015, Nonacus established itself with a clear mission: to prioritize the end-user by providing high-quality, non-invasive genetic testing.

Our team consists of passionate biotechnology experts, including professionals from the NHS and international genome projects, committed to delivering continuous progress. This deep understanding forms the foundation of our product development and fuels our drive for innovation.

informed-genomics-philosophy.png

About
Informed Genomics

At Informed Genomics we place quality at the heart of everything we do. The patient is our priority and we strive to provide the right testing that has a meaningful impact on an individual’s healthcare experience and outcomes. We are focussed on providing innovative testing solutions that can empower an individual in their healthcare choices.

Our core team has extensive experience in clinical and translational genomic testing and we are dedicated to using this experience to provide the best solution for both clinical diagnostics and genomic research projects.

What is GALEAS

A highly optimized NGS approach to modern day genomic cancer profiling, able to identify CNVs, INDELS, MSI and TMB in both solid and liquid biopsies without having to waste time and resources on MLPA assays.

GALEAS Tumor

  • A large coverage assay of 519 genes accounting for more than 90% of all global cancer cases
     

  • Confidently identifies somatic variants with 100% recall and precision

GALEAS Bladder

  • Non-invasive detection of all stages of bladder cancer 
     

  • >90% detection rate in early tumor state beating existing techniques
     

  • Reducing cost and pain of current detection and monitoring strategies

GALEAS Hereditary 

  • Covers 146 Carefully selected genes
     

  • Also covers rarer hereditary cancer types like Phaeochromocytoma and pediatric cancers like Wilms tumor

Nonacos Website Materials_Section Banner 2.jpg
bottom of page